NORGES BANK - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 174 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 0.46 and the average weighting 0.2%.

Quarter-by-quarter ownership
NORGES BANK ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2022$281,373
-0.2%
17,2940.0%0.00%
Q4 2021$282,000
+9.7%
17,2940.0%0.00%
Q3 2021$257,000
-90.0%
17,294
-86.5%
0.00%
-100.0%
Q2 2021$2,558,000
+11.9%
128,071
+29.3%
0.00%0.0%
Q1 2021$2,286,000
-52.2%
99,035
-48.9%
0.00%0.0%
Q4 2020$4,782,000
-32.8%
193,621
+12.9%
0.00%
-50.0%
Q3 2020$7,112,000
-40.3%
171,545
-31.0%
0.00%
-33.3%
Q2 2020$11,916,000
-40.9%
248,708
-22.3%
0.00%
-57.1%
Q1 2020$20,161,000
-46.1%
320,216
+6.0%
0.01%
-30.0%
Q4 2019$37,422,000
+86.7%
301,9880.0%0.01%
+66.7%
Q3 2019$20,040,000
-16.6%
301,9880.0%0.01%
-14.3%
Q2 2019$24,029,000
-23.8%
301,988
+7.1%
0.01%
-30.0%
Q1 2019$31,549,000
+11.0%
282,0450.0%0.01%
-9.1%
Q4 2018$28,428,000
-20.2%
282,0450.0%0.01%
-8.3%
Q3 2018$35,639,000
+126.2%
282,045
+50.2%
0.01%
+140.0%
Q2 2018$15,756,000
+647.4%
187,769
+448.0%
0.01%
+400.0%
Q1 2018$2,108,000
+124.5%
34,265
+113.3%
0.00%
Q4 2017$939,000
+0.8%
16,0650.0%0.00%
Q3 2017$932,000
+38.5%
16,065
+189.1%
0.00%
Q2 2017$673,000
-91.7%
5,557
-92.3%
0.00%
-100.0%
Q1 2017$8,130,000
-53.9%
71,881
-55.8%
0.00%
-62.5%
Q4 2016$17,652,000
-20.6%
162,465
+14.9%
0.01%
-27.3%
Q3 2016$22,223,000
+28.7%
141,367
+16.8%
0.01%
+37.5%
Q2 2016$17,266,000
+59.0%
121,012
+43.2%
0.01%
+60.0%
Q1 2016$10,860,000
-40.8%
84,531
-31.2%
0.01%
-44.4%
Q4 2015$18,351,000
-10.0%
122,8730.0%0.01%
-18.2%
Q3 2015$20,380,000
-34.1%
122,873
-4.1%
0.01%
-26.7%
Q2 2015$30,934,000
-14.4%
128,1550.0%0.02%
-16.7%
Q1 2015$36,142,000
+88.2%
128,155
+4.1%
0.02%
+80.0%
Q4 2014$19,201,000
-34.1%
123,0830.0%0.01%
-37.5%
Q3 2014$29,132,000
-50.0%
123,083
-50.0%
0.02%0.0%
Q2 2014$58,250,000
+376.3%
246,166
+563.8%
0.02%
+128.6%
Q1 2014$12,230,00037,0830.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2014
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders